Overview
Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency.
Indication
For immediate reduction of blood pressure of patients in hypertensive crises, reduce bleeding during surgery, and for the treatment of acute congestive heart failure
Associated Conditions
- Acute Heart Failure (AHF)
- Hypertensive crisis
- Intraoperative Blood Loss
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/07/25 | Early Phase 1 | Recruiting | |||
2024/06/05 | N/A | Recruiting | |||
2024/05/22 | Phase 2 | Recruiting | |||
2023/09/21 | N/A | Active, not recruiting | |||
2022/09/01 | Not Applicable | Completed | |||
2022/03/14 | Phase 1 | Completed | |||
2022/01/18 | Not Applicable | Recruiting | |||
2021/08/30 | N/A | Completed | |||
2021/08/02 | Phase 2 | Terminated | |||
2021/06/16 | Not Applicable | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Somerset Therapeutics, LLC | 70069-261 | INTRAVENOUS | 25 mg in 1 mL | 12/14/2023 | |
| Dr.Reddy's Laboratories Inc., | 43598-587 | INTRAVENOUS | 50 mg in 2 mL | 12/22/2016 | |
| Caplin Steriles Limited | 65145-101 | INTRAVENOUS | 50 mg in 2 mL | 11/29/2017 | |
| Slate Run Pharmaceuticals, LLC | 70436-207 | INTRAVENOUS | 0.5 mg in 1 mL | 11/15/2023 | |
| Hainan Poly Pharm. Co., Ltd. | 14335-132 | INTRAVENOUS | 0.2 mg in 1 mL | 12/31/2022 | |
| Amneal Pharmaceuticals LLC | 70121-1189 | INTRAVENOUS | 25 mg in 1 mL | 12/27/2023 | |
| Hainan Poly Pharm. Co., Ltd. | 14335-134 | INTRAVENOUS | 0.5 mg in 1 mL | 12/31/2022 | |
| Nexus Pharmaceuticals Inc | 14789-012 | INTRAVENOUS | 25 mg in 1 mL | 5/9/2022 | |
| Slate Run Pharmaceuticals, LLC | 70436-205 | INTRAVENOUS | 0.2 mg in 1 mL | 11/15/2023 | |
| Slate Run Pharmaceuticals, LLC | 70436-206 | INTRAVENOUS | 0.2 mg in 1 mL | 11/15/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Sodium Nitroprusside Injection | 国药准字H20223226 | 化学药品 | 注射剂 | 4/12/2022 | |
| Sodium Nitroprusside Injection | 国药准字H20249215 | 化学药品 | 注射剂 | 10/29/2024 | |
| Sodium Nitroprusside for Injection | 国药准字H20084100 | 化学药品 | 注射剂 | 7/5/2023 | |
| Sodium Nitroprusside for Injection | 国药准字H20054269 | 化学药品 | 注射剂 | 12/11/2020 | |
| Sodium Nitroprusside for Injection | 国药准字H20083887 | 化学药品 | 注射剂 | 1/5/2023 | |
| Sodium Nitroprusside for Injection | 国药准字H20065354 | 化学药品 | 注射剂 | 8/15/2024 | |
| Sodium Nitroprusside for Injection | 国药准字H20084203 | 化学药品 | 注射剂 | 7/26/2023 | |
| Sodium Nitroprusside for Injection | 国药准字H20052144 | 化学药品 | 注射剂(冻干粉针剂) | 7/23/2021 | |
| Sodium Nitroprusside for Injection | 国药准字H20033674 | 化学药品 | 注射剂 | 11/6/2020 | |
| Sodium Nitroprusside for Injection | 国药准字H20058959 | 化学药品 | 注射剂(冻干粉针剂) | 9/21/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Help Us Improve
Your feedback helps us provide better drug information and insights.